Search

Voclosporin

Early and accurate intervention for LN is important in improving clinical outcomes. … [L31253] In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended voclosporin be granted marketing authorization for use in combination with [mycophenolate mofetil]

Garadacimab

[A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [A273993,A273998] As opposed to [lanadelumab], another prophylactic agent for HAE that targets kallikrein, garadacimab targets activated factor XII, the first factor in the contact system responsible for

Dutasteride

Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to … However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled

Lanolin

For this reason, it is also called wool wax or wool grease. Lanolin is used in the protection, treatment, and cosmetic enhancement of human skin. … Lanolin is also frequently used in protective baby skin treatment and for sore nipples in breastfeeding mothers [L2583], [A32788].

Fenproporex

Fenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. … The N-2-cyanoethyl substituent was once believed to be resistant to cleavage, because fenproporex -- once recommended as an obesity treatment for patients with cardiovascular disease -- was originally

Afatinib

Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected

Trandolapril

It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. … for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Porphobilinogen deaminase, human recombinant

Remoxipride

[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512] … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D₂ receptors.